MINI FUTURE LONG - MODERNA | Market Closed - Euronext Paris 12:30:02 2024-07-05 pm EDT | ||
| 4.78 EUR | -5.53% |
|
| Current month | -4.72% | ||
| 1 month | -39.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 4.85 | -4.15% |
| 24-07-04 | 5.06 | +6.75% |
| 24-07-03 | 4.74 | -0.84% |
| 24-07-02 | 4.78 | -1.24% |
| 24-07-01 | 4.84 | -4.91% |
Real-time Euronext Paris
Last update July 05, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| FE4MB | |
| ISIN | NLBNPNL2K3T9 |
| Date issued | 2023-11-07 |
| Strike | 64.69 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.67 € |
|---|---|
| Lowest since issue | 0.6 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Certificates
- FE4MB Certificat
